| 1 |
34463889 | Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen. | 2022 Feb |
1 |
| 2 |
33258078 | Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study. | 2021 Apr |
2 |
| 3 |
33547330 | The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. | 2021 Feb 5 |
1 |
| 4 |
33596096 | Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer. | 2021 Jun |
1 |
| 5 |
33737962 | High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study. | 2021 |
4 |
| 6 |
33805613 | Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer. | 2021 Mar 13 |
1 |
| 7 |
33905134 | Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer. | 2021 Apr 27 |
1 |
| 8 |
33910628 | Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report. | 2021 Apr 29 |
5 |
| 9 |
33996592 | Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer. | 2021 |
1 |
| 10 |
34209871 | NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer. | 2021 Jun 29 |
10 |
| 11 |
34359587 | From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells. | 2021 Jul 22 |
1 |
| 12 |
34402131 | Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor. | 2021 Nov |
2 |
| 13 |
34414958 | Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis. | 2021 Aug 20 |
2 |
| 14 |
34543613 | Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. | 2021 Oct |
1 |
| 15 |
34720808 | Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. | 2021 Oct |
1 |
| 16 |
34830800 | Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement. | 2021 Nov 11 |
1 |
| 17 |
34868931 | Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics. | 2021 |
2 |
| 18 |
31618131 | Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. | 2020 Apr 20 |
8 |
| 19 |
32352244 | Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. | 2020 Jul |
1 |
| 20 |
32367072 | Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis. | 2020 Jul |
1 |
| 21 |
32398983 | Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases. | 2020 Apr |
1 |
| 22 |
32926316 | Clinical practice to address tamoxifen nonadherence. | 2020 Dec |
1 |
| 23 |
33324567 | Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells. | 2020 |
1 |
| 24 |
29687661 | Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence. | 2019 Jan |
1 |
| 25 |
30478785 | G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen. | 2019 Feb |
1 |
| 26 |
30980508 | Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor-positive breast and prostate cancer cells. | 2019 Aug |
2 |
| 27 |
31051411 | Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. | 2019 Aug |
1 |
| 28 |
31146160 | Impacts of in vivo and in vitro exposures to tamoxifen: Comparative effects on human cells and marine organisms. | 2019 Aug |
2 |
| 29 |
31153828 | circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. | 2019 Sep 4 |
2 |
| 30 |
31331091 | Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer. | 2019 Jul 19 |
1 |
| 31 |
31340867 | The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. | 2019 Jul 24 |
1 |
| 32 |
30197363 | Lobular breast cancer metastasis to uterus during adjuvant tamoxifen treatment: A case report and review of the literature. | 2018 Jul-Sep |
1 |
| 33 |
30358233 | Should addition of five years of ovarian suppression to tamoxifen be "must" for hormone receptor positive and HER-2 positive breast cancer under the age of 35? | 2018 Jul-Aug |
1 |
| 34 |
30536272 | Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer. | 2018 Dec |
2 |
| 35 |
27815995 | Impairment of the executive attention network in premenopausal women with hormone receptor-positive breast cancer treated with tamoxifen. | 2017 Jan |
1 |
| 36 |
28293118 | CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study. | 2017 |
1 |
| 37 |
28422735 | Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance. | 2017 May 30 |
1 |
| 38 |
28601930 | Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy. | 2017 Sep |
2 |
| 39 |
28785180 | Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer. | 2017 Jul |
1 |
| 40 |
25900861 | Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years. | 2016 Apr |
4 |
| 41 |
26482374 | Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients. | 2016 Jun |
2 |
| 42 |
27012810 | Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility. | 2016 Jul 1 |
1 |
| 43 |
27117241 | Adjuvant Surgical Oophorectomy Plus Tamoxifen in Premenopausal Women With Operable Hormone Receptor-Positive Breast Cancer: A Global Treatment Option. | 2016 Aug |
1 |
| 44 |
27264120 | Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. | 2016 Jul 21 |
1 |
| 45 |
26417636 | Breast cancer and duration of tamoxifen. | 2015 Sep |
1 |
| 46 |
23184499 | Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients. | 2014 Sep |
1 |
| 47 |
23755153 | The effect of antineoplastic drugs in a male spontaneous mammary tumor model. | 2014 |
1 |
| 48 |
24434530 | Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report. | 2014 Jan-Feb |
1 |
| 49 |
24857109 | Endocrine therapy toxicity: management options. | 2014 |
1 |
| 50 |
25199766 | Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective. | 2014 Sep 9 |
2 |